Sartorius Stedim Biotech S.A.
High uncertainty:The valuation methods show significant disagreement (>100% spread). Treat the range as a rough guide rather than a precise estimate.
Bear Case (25th pct.)
-97.3% vs price
Base Case (Median)
-95.0% vs price
Bull Case (75th pct.)
-89.4% vs price
◇ = Current price | |Bear |Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $0.03 | -99.8% | High (40%) |
| PE Comparable | $2.00 | -89.2% | Medium (25%) |
| Growth Trajectory DCF | $1.96 | -89.4% | Medium (20%) |
| Graham Number | $0.92 | -95.0% | Medium (40%) |
| EV/FCF | $0.50 | -97.3% | Medium (20%) |
Based on 5 out of 8 methods, SRTOY appears overvalued at the current price of $18.55. The base case fair value of $0.92 implies 95.0% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.